Please find enclosed Annual report 2024-25 of Godavari Drugs Limited
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs Limited has submitted its 37th Annual Report for FY 2024-25 along with the notice for its 37th Annual General Meeting, scheduled for September 27, 2025 via video conferencing. The company reported revenue from operations of ₹11,335.01 lakhs, a significant drop from ₹15,671.19 lakhs in the previous year (about 28% decline). Despite the revenue fall, EBIDTA margin expanded notably to 11.30% from 8.88%, and PAT margin improved to 3.86% from 3.54%. Profit After Tax stood at ₹438.00 lakhs (down from ₹554.89 lakhs), with EPS of ₹5.82. Key AGM items include reappointment of Managing Director Mr. Mukund Kakani, appointment of Mrs. Shilpa Bung as Independent Director, and a proposal to double authorized share capital from ₹10 crore to ₹20 crore, hinting at future fundraising or expansion plans.
For shareholders, the sharp revenue decline is a concern, but improving margins suggest better cost discipline and a richer product mix. The proposed doubling of authorized share capital signals potential capital-raising activity that could dilute existing holdings. A new API manufacturing facility expected to commission by year-end may support future growth.